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Abstract  
Introduction: The progression of Ductal Carcinoma in situ (DCIS) to Invasive Ductal 
Carcinoma (IDC) marks a critical step in the evolution of breast cancer. There is some 
evidence to suggest that dynamic interactions between the neoplastic cells and the tumour 
microenvironment play an important role.  
Methods: Using the Whole-Genome cDNA-mediated Annealing, Selection, extension and 
Ligation assay (WG-DASL, Illumina), we performed gene expression profiling on 87 
formalin-fixed paraffin embedded (FFPE) samples from 16 patients consisting of matched 
IDC, DCIS and three types of stroma: IDC-S (<3 mm from IDC), DCIS-S (<3 mm from 
DCIS) and BC-NS (Breast Cancer associated - Normal Stroma; >10 mm from IDC or DCIS). 
Differential gene expression analysis was validated by quantitative Real Time-PCR, 
immunohistochemistry and immunofluorescence.  
Results:  The expression of several genes was down-regulated in stroma from cancer patients 
relative to normal stroma from reduction mammoplasties. In contrast, neoplastic epithelium 
underwent more gene expression changes during progression, including down regulation of 
SFRP1. In particular, we observed that molecules related to extracellular matrix remodelling 
(e.g. COL11A1, COL5A2 and MMP13) were differentially expressed between DCIS and IDC. 
COL11A1 was overexpressed in IDC relative to DCIS and was expressed by both the 
epithelial and stromal compartments but was enriched in invading neoplastic epithelial cells.  
Conclusions: We have investigated the contributions of both the epithelial and stromal 
compartments to the clinically important scenario of progression from DCIS to IDC. 
Comparing IDC and DCIS gene expression profiles, we identified differential expression of 
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genes related to extracellular matrix remodeling, and specifically the elevated expression of 
‘stromal’ genes such as COL11A1, COL5A2 and MMP13 in epithelial cells of IDC. We 
propose that these expression changes could be involved in facilitating the transition from in 
situ disease to invasive cancer and may thus mark a critical point in disease development. 
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RM, Reduction Mammoplasty 
RM-NS, Reduction Mammoplasty Normal Stroma 
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assay 
Introduction 
The multistep model of breast cancer progression is based on the morphological evolution 
from Atypical Ductal Hyperplasia (ADH) to Ductal Carcinoma in situ (DCIS) to Invasive 
Ductal Carcinoma (IDC) [1-3]. Gene expression profiling-based studies have failed to 
demonstrate significant differences between these different stages of progression and instead 
have shown that multiple samples from an individual patient cluster closer to one another 
than to their respective stage of progression (ADH, DCIS and IDC) [4-7].  These, and other 
studies (combination of genomic, gene expression and immunohistochemical), suggest that 
the molecular phenotype is already established at the ADH/DCIS stage and does not change 
considerably as DCIS progresses to invasive cancer [2, 8-10]. Nevertheless some subtle 
alterations have been identified and relate to processes such as epithelial mesenchymal 
transition, extracellular matrix and matrix remodeling, and proliferation [5, 6, 11]. 
It is becoming increasingly apparent that the tumour micro-environment plays a key role in 
defining tumour behaviour and patient outcome. Gene expression changes occur in cancer-
associated stroma and are known to be implicated in prognosis as well as in cancer 
progression [5, 12-15]. Specifically, Ma et al. provided strong evidence from gene expression 
profiling that the stroma co-evolves with the epithelial compartments during progression [5].  
Gene expression profiling of breast cancer progression has so far only been studied using 
fresh frozen (FF) material [5] owing to the highest quality of RNA being available from this 
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sample type. However, formalin-fixed paraffin-embedded tissue (FFPE) archives also 
provide a valuable resource for clinical research with wide availability of samples, 
particularly for different stages of progression. Gene expression profiling of FFPE clinical 
samples is also now feasible due to recent technological advances [16, 17]. Here we present 
the application of Whole-Genome cDNA-mediated Annealing, Selection, extension and 
Ligation assay (WG-DASL, Illumina) [16, 17] to the study of the transition of DCIS to IDC 
in the context of both epithelial and stromal compartments. 
 
MATERIALS AND METHODS 
Tissue Samples: FF and archival FFPE material was accessed locally with approval from the 
Human Research Ethics Committee of the Royal Brisbane and Women’s Hospital (RBWH) 
and The University of Queensland. FFPE blocks from 17 patients diagnosed with concurrent 
IDC and DCIS between 2007 and 2009 were selected for gene expression profiling (Table 1). 
All cases were pure Invasive Ductal Carcinoma No Special Type (IDC NST) (n=14) or mixed 
ductolobular (n=3; ductal component exclusively studied), of histological grade 2 or 3 [18, 
19]). Only IDCs with solid or glandular pattern with minimal intervening stroma were used. 
Three types of breast interlobular stroma were studied: IDC-S (stroma within 3 mm of IDC), 
DCIS-S (stroma within 3 mm of DCIS) and BC-NS (stroma >10 mm from IDC and/or 
DCIS), Figure 1. The BC-NS was obtained from either the same (n=5) or an alternative 
paraffin block (n=11) to the IDC/DCIS lesion. Additional cohorts of samples used, including 
reduction mammoplasties (RM, free from inflammation and fibrocystic change) are detailed 
in Online Resource Table S1. 
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RNA extraction and Quantitative Real Time PCR (qRT-PCR): Manual microdissection 
of epithelial (IDC and DCIS) and stromal compartments was performed, by a pathologist, 
using a stereomicroscope and a sterile needle. Up to 15 tissue sections for DCIS and IDC and 
40-50 sections for the corresponding stromal samples were required. RNA was isolated using 
the High Pure RNA Paraffin kit (Roche Diagnostics Australia Pty Ltd., Castle Hill, NSW, 
Australia). cDNA synthesis was performed using 250 ng of total RNA and SuperScript™ III 
(Invitrogen Australia Pty Ltd., Mulgrave, VIC, Australia). TaqMan Gene Expression Assays 
(Applied Biosystems, Mulgrave, VIC, Australia; COL11A1, Hs00266273_m1; COL17A1, 
Hs00990073_m1; SFRP1, Hs00610060_m1; SOX10, Hs00366918_m1; MMP13, 
Hs00233992_m1; ABCB1, Hs01067802_m1 and MRAP2, Hs00536621_m1; USP19, 
Hs01103458_m1) were selected for qRT-PCR. Relative quantification using the comparative 
ΔΔCt method was performed [20], normalised to the endogenous control (RPL13A, 
Hs03043885_g1).  A reference sample consisting of equal proportions of epithelial and 
stromal material was pooled from three RMs. The Mann-Whitney U statistical test was used 
to determine significance (P<0.05).  
Gene Expression Profiling and Data Analysis: Whole Genome DASL (Illumina, Scoresby, 
VIC, Australia) was performed as previously described [16]. Briefly, 86/91 RNA samples 
met the quality criteria (adequate RNA concentration and a Ct value of <29, as determined by 
qRT-PCR for RPL13A; samples from case 5 failed qRT-PCR and so were omitted from 
subsequent experiments). 200 ng of RNA was processed using the MCS2 reagent and 
hybridised to the Human Ref8_V3_BeadChips. Data was collated using GenomeStudio 
(Illumina). The lumi [21] and limma [22] Bioconductor software packages using R (version 
2.13.0) were used to perform quantile normalisation and determine differential expression 
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respectively. Genes with Benjamini and Hochberg adjusted P-values (<0.05) with a greater 
than 50% chance of being differentially expressed (positive B-statistic) were considered 
differentially expressed. Genespring GX 10.0.2 (Agilent Technologies, Mulgrave, VIC, 
Australia) was used for data visualisation and Gene Ontology (GO) analysis using P<0.05. 
Normalised data can be accessed from GEO (GSE35019; 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=nxidrscqqwgqqfe&
acc=GSE35019).   
 
Immunohistochemistry (IHC) and Immunofluorescence (IF) and Analysis 
IHC for SFRP1 (1:200; clone ab4193, Abnova, Taipei City, Taiwan) and SOX10 (1:200; 
clone N-20; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was performed on FF and 
FFPE sections, respectively. The MACH 1 Universal HRP-Polymer kit (Biocare Medical, 
Concord, CA, USA) was used for detection. Percentage and intensity (weak = 1+, moderate = 
2+, strong = 3+) of positive cytoplasmic and/or nuclear staining in normal and tumour 
epithelial cells was scored. Dual Immunofluorescence (IF) for COL11A1 and CK8/18 was 
performed, scored and analysed as described (Online Resource Figures S1 and S2). 
RESULTS 
WG-DASL Gene Expression Profiling 
Of the 87 samples analysed by WG-DASL (Table 1), 69 passed average signal intensity 
(>250) and P95 (>800) criteria as described in [16]. Five IDC samples were performed in 
duplicate and showed an r2 value between 0.89 and 0.97 (Online Resource Figure S3); 22,723 
probes showed a reliable detection score (P<0.01) in at least one sample. Unsupervised 
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hierarchical clustering of probes which differed 2 fold from the mean (10,870 probes) showed 
that, apart from seven samples, there was a clear separation between stromal and epithelial 
samples (Figure 2A).  In total, 64 probes representing 58 genes were differentially expressed 
between IDC and DCIS (Table 2), of which 42 and 16 genes were up- and down-regulated in 
DCIS compared to IDC, respectively. Clustering of these 58 genes in the epithelial samples 
(DCIS and IDC) showed three main subgroups (Figure 2B): group 1 contained predominantly 
grade 3 IDC patients, group 2 contained a mixed group of both IDC and DCIS while group 3 
contained only DCIS samples.  
 
Unsupervised clustering (Figure 2C) separated normal stroma from healthy patients (RM-NS) 
and breast cancer patients (BC-NS). No obvious stratification was observed between the three 
types of stroma from breast cancer patients (BC-NS, IDC-S, DCIS-S) and no significantly 
differentially expressed genes were identified between any of these sample comparisons (i.e. 
IDC-S vs BC-NS; IDC-S vs DCIS-S; DCIS-S vs BC-NS). However, pairwise comparison of 
the cancer stromal types with the RM-NS samples showed that the same genes were 
consistently expressed at lower levels in the cancer stroma. Indeed, ten genes were 
differentially expressed between IDC-S and RM-NS and five of these were differentially 
expressed between DCIS and RM-NS (Table 2). Furthermore, two of these genes, USP19 and 
MRAP2, were significantly differentially expressed between the two most ‘normal’ stromal 
samples, RM-NS and BC-NS, while ABCB1 was down-regulated in all cancer-associated 
stromal samples compared to RM-NS. 
 
Verification of microarray data by qRT-PCR 
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To validate the WG-DASL findings, qRT-PCR relative quantitation was performed for a 
selection of biologically interesting transcripts (COL17A1, COL11A1, SFRP1, SOX10, 
MMP13, ABCB1, USP19, MRAP2). MMP13, also known as Collagenase-3, has been widely 
studied in breast cancer, where it has been shown that it can promote the DCIS to IDC 
transition [23, 24]. COL11A1 encodes a minor collagen found in many tissues; its expression 
has been shown to be dysregulated in cancers such as breast and colon [25-28]. COL17A1 is a 
transmembrane protein expressed in normal breast and involved in cell adhesion and SOX10, 
a transcription factor of the SRY family of the high mobility group box family, is known to 
be expressed in normal myoepithelial cells [29]. The SFRP1 gene, located at 8p11-21, is 
frequently lost or down-regulated in sporadic breast cancer and is involved in cancer 
progression [30]. The MRAP2 (Melanocortin-2 receptor accessory protein 2) gene encodes a 
protein-coupled receptor protein, which regulates adrenocorticotropic hormone signalling 
[31], while USP19 is a de-ubiquitinating enzyme induced in skeletal muscle atrophy. ABCB1, 
also known as MDR1 (Multidrug resistance gene 1), encodes a glycoprotein (PgP) that acts as 
an efflux pump, protecting the cells from xenobiotics [32] and has been implicated in breast 
cancer chemoresistance [33]. 
 
Three of five genes that were differentially expressed in DCIS vs. IDC WG-DASL 
comparisons (SOX10, COL11A1 and MMP13) were confirmed as being differentially 
expressed by qRT-PCR (P<0.05, Figure 3A and 3B). There is considerable variation in 
expression levels between samples, as expected for human tumour samples. While WG-
DASL and qRT-PCR data for COL17A1 expression was inconsistent, SFRP1 showed a 
consistent trend, and with removal of the two highest expressing IDC samples, significance 
was achieved (P≤0.01).  These two samples are the only ‘triple negative’ tumours in the 
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cohort (Table 1) and this phenotype is known to be associated with overexpression of SFRP1 
(Online Resource Figure S4, [34]). COL11A1 was significantly up-regulated in IDC 
compared to both DCIS (P<0.0001) and to its surrounding stroma (IDC-S; P=0.012, Figure 
3B). IDC-S exhibited variable expression levels of COL11A1, but overall showed a 
significantly higher expression than the DCIS-S (P=0.007). DCIS-S and BC-NS stromal 
samples and those from reduction mammoplasties showed consistently low levels of 
COL11A1 expression relative to IDC and IDC-S, with no significance observed in 
comparisons between the RM-NS and BC-NS samples (Figure 3B).  
 
For the genes exclusively targeted in the stromal compartment, variable expression was 
detected. Two of four transcripts validated, again reflecting variability in human clinical 
samples; DCIS-S sample material was also limiting preventing strong correlations from being 
made (Figure 3C). ABCB1 stromal transcripts showed concordance with the WG-DASL data, 
being significantly down-regulated in cancer stroma samples relative to the RM-NS (IDC-S, 
P<0.001 and BC-NS, P<0.05). MRAP2 qRT-PCR data did not replicate that of the WG-
DASL, however, the cancer stroma shows a trend towards bimodality of expression, with 
divergent groups of high- and low- expressing samples. Exclusion of these ‘high-expressors’ 
in BC-NS and DCIS-S results in significantly lower levels of expression relative to the RM-
NS, as observed by WG-DASL. USP19 expression was significantly different between the 
RM-NS and BC-NS samples (P=0.008) yet contradicted the WG-DASL data, however the 
presence of a single high expressing BC-NS sample likely skewed the statistics towards 
significance.  
 
Verification of microarray data by IHC and IF 
This is a post-print version of the following article: Vargas, Ana Cristina, McCart Reed, Amy E., 
Waddell, Nic, Lane, Annette, Reid, Lynne E., Smart, Chanel E., Cocciardi, Sibylle, da Silva, Leonard, 
Song, Sarah, Chenevix-Trench, Georgia, Simpson Peter T. and Lakhani, Sunil R. (2012) Gene 
expression profiling of tumour epithelial and stromal compartments during breast cancer 
progression. Breast Cancer Research and Treatment, 135 1: 153-165.  
 
To validate expression changes at the protein level, we performed IHC for SFRP1 and 
SOX10, and IF for COL11A1 in independent cohorts of cases (Online Resource Table S2). 
SFRP1, evaluated in frozen tissue sections (Figure 4A-C), was expressed in the cytoplasm of 
luminal cells of all normal TDLUs assessed (median percentage of cells stained: 100%; range 
20-100%). A significant decrease in expression was observed in DCIS (median: 30%; range 
10-40%; P=0.004) and in IDC (median: 20%; range 0-60% P=0.0001) relative to the normal. 
There was no significant difference between DCIS and IDC. SOX10 was strongly expressed 
in normal myoepithelial cells of TDLUs and surrounding DCIS, however, expression was not 
detected in normal luminal epithelial cells, nor in 104/105 DCIS and invasive cancers (Figure 
4).  
We performed IF staining on frozen sections to assess COL11A1 expression in the different 
breast compartments; epithelial localisation of COL11A1 was confirmed by co-staining with 
CK-8/18 (Online Resource Figure S2). High levels were observed in the normal epithelium 
(NE) from both breast cancer (BC-NE) and healthy patients (RM-NE; mean signal intensity, 
point analysis: 74.7 and 63.9, respectively). COL11A1 expression was higher in IDC 
compared to DCIS (mean signal intensity, point analysis; 73.9 vs 51.5, respectively), 
although this observation agreed with mRNA data, it was not significant, likely owing to 
limited sample size (Figure 5). While COL11A1 was also expressed in both normal, and 
neoplastic stroma, this expression was significantly lower compared to that of the epithelial 
compartments (BC-NE, DCIS and IDC, P≤0.001). Fibroblasts were also shown to express 
COL11A1 (Online Resource Figure S5).  
 
Gene Ontology Analysis and MetaAnalysis 
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The list of genes differentially expressed between DCIS and IDC (n=58) was subjected to 
Gene Ontology (GO) analysis in an effort to identify the cellular pathways and processes that 
might be involved in the transition to invasive cancer (Online Resource Table S3). An 
interesting feature of this list was that 11/58 genes were associated with the extracellular 
matrix. In order to investigate whether stromal contamination was prompting the enrichment 
for ECM terms, we attributed GO terms to the ‘Schuetz’ gene list (LCM dissected, FF DCIS 
vs. matched IDC [6]) and also found an enrichment for functional terms related to ECM  
(Online Resource Table S3).  
Specifically, eight probes were shared between the Schuetz list and our own accounting for 
three genes: COL11A1, COL5A2 and MMP13. Comparing our differentially expressed gene 
list with another recent analysis of DCIS to IDC transition using a LCM-based approach [11], 
we found 11 genes to be shared. Intriguingly, of these 11 genes, there were six different 
collagens and three high molecular weight keratins (COL10A1, COL11A1, COL12A1, 
COL17A1, COL5A2, COL8A1, GPC6, KRT14, KRT17, KRT5, MYH11). We did not find any 
overlap between our stromal list and that of Knudsen et al [11], nor with Hannemann et al. 
[35] who reported a 35-gene signature that can distinguish DCIS from IDC.  
 
 
DISCUSSION 
We have applied gene expression profiling technology (WG-DASL, using MCS2 version 
reagents) to FFPE tissues to analyze the breast epithelial and stromal compartments in the 
context of tumour progression. Technically, the WG-DASL was successful, with five 
replicate pairs correlating well, ~80% samples passing internal control criteria and epithelial 
This is a post-print version of the following article: Vargas, Ana Cristina, McCart Reed, Amy E., 
Waddell, Nic, Lane, Annette, Reid, Lynne E., Smart, Chanel E., Cocciardi, Sibylle, da Silva, Leonard, 
Song, Sarah, Chenevix-Trench, Georgia, Simpson Peter T. and Lakhani, Sunil R. (2012) Gene 
expression profiling of tumour epithelial and stromal compartments during breast cancer 
progression. Breast Cancer Research and Treatment, 135 1: 153-165.  
 
and stromal samples stratifying as expected following unsupervised hierarchical clustering. 
Previous WG-DASL studies have focused on the technical feasibility of the assay, through 
for example, FF vs FFPE comparisons [17, 36, 37] and the validation of candidate genes (e.g. 
ER [38], Her2 [39]) related to subtyping of breast cancers. Nevertheless, gene expression 
profiling of archival FFPE samples remains extremely challenging, particularly for discovery 
approaches to understand important biological and/or clinical scenarios, as has been 
attempted here with respect to tumour progression. We were able to validate 5/9 differentially 
expressed genes using qRT-PCR and immunological techniques although we observed 
considerable variation in the expression levels of some transcripts across the clinical samples. 
It is difficult to conclude confidently whether this validation rate is appropriate, given the 
relatively limited number of published WG-DASL studies and that the starting material is 
FFPE, and therefore of highly variable quality. We would advocate validation of a larger 
panel of transcripts however, in this instance, clinical material was limiting.   
The putative tumor suppressor, Secreted frizzled-related protein 1 (SFRP1) [40] was 
identified by WG-DASL as being down-regulated during progression from DCIS to IDC, 
consistent with other reports [41,5,42]. However this pattern of expression was validated by 
qRT-PCR only when the two high expressing IDC were removed from analysis. These 
‘outliers’ were the only triple negative tumours in the cohort studied and together with our 
meta-analysis of publically available microarray data (Online Resource Figure S4) confirms 
reports that loss of SFRP1 expression is associated with hormone receptor positivity [42] and 
conversely is a key phenotypic marker in some basal-like tumours [34]. Interestingly, the 
gene resides on chromosome 8p11-12 within the complex and variable amplification that is 
identified in ~10-15% of breast cancers [43, 44] suggesting that its expression levels might be 
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dictated in part by which specific genomic fragments are lost or gained during establishment 
of the amplicon. The role of SFRP1 as a tumour suppressor in progression may therefore be 
restricted to certain tumour subtypes (luminal and HER2 related) and possibly a proportion of 
basal-like/triple negative tumours. 
Contrary to previous reports [4, 5, 7], we did not observe an enrichment of cell cycle-related 
genes differing between DCIS and IDC compartments. This observation, however, maybe a 
reflection of study design; the earlier studies used a mixture of low and high-grade tumours, 
whereas the current study used a more homogeneous cohort of mostly grade 3 tumours. It is 
perhaps as a consequence of this that we found just 58 differentially expressed genes between 
these epithelial components, highlighting the overall similarity between matched cases of 
DCIS and IDC. This is exemplified by the fact that a number of the genes ‘down-regulated’ 
in IDC compared to DCIS in this study are specific myoepithelial markers (e.g. SOX10, 
KRT14, KRT5, KRT17; Table 2) and as such were derived from only small population of 
DCIS-associated myoepithelial cells (Figure 4). The high molecular weight cytokeratins are 
well established myoepithelial markers, whereas SOX10 was only recently described as a 
specific marker of normal myoepithelial cells [29]. The presence of SOX10 positive DCIS-
associated myoepithelial cells, which were included in the micro-dissection of the DCIS 
samples, would account for the apparent SOX10 over-expression seen in DCIS relative to 
IDC by WG-DASL and qRT-PCR analyses.  
Despite the lack of overlap in gene lists between the current study and previous reports [4, 5, 
35] there remains some common gene families and biological processes that are featured in 
the transition of DCIS to IDC. For instance, in the current study there were a number of genes 
differentially expressed between DCIS and IDC epithelia that are related to the extracellular 
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matrix (e.g. COL17A, COL5A2, COL22A1, COL8A1, COL12A1, COL10A1, COL11A1, 
MMP13, GPC6, KLK5, FREM1). Comparisons with reported studies [6, 11, 28, 45] 
supported our finding that the epithelial compartment is producing ECM-related components. 
Specifically, we showed by gene expression profiling, qRT-PCR and IF that COL11A1 is 
produced by the tumour epithelial cells to significantly higher levels than DCIS and the 
immediate adjacent stroma (IDC-S, <3 mm) suggesting that COL11A1, among other ECM 
proteins, might play a role in local invasion of breast cancer cells. In support of this, altered 
expression of COL11A1 has frequently been associated with tumour development and/or 
progression by others. Significant differential expression of this gene was recently reported to 
be the top hit in an array-based comparison of DCIS and IDC stroma and epithelium [11]. 
Turashvili et al., found COL11A1 to be differentially up-regulated in invasive ductal and 
lobular carcinomas compared to normal epithelium (>6-fold change; [45]). Additionally, 
COL11A1 epithelial expression has also been demonstrated at the protein level, not only in 
breast tissue [28] but also in colorectal epithelium [25]. The co-expression and concomitant 
up-regulation of COL11A1 with COL5A2 has previously been shown in colorectal cancer 
compared to its precursor lesion [26, 27], which is in agreement with our data that showed 
up-regulation of both these genes in IDC relative to DCIS.  Importantly, COL11A1 was found 
to be the top ranked gene in a late-stage ovarian, colorectal and breast cancer meta-analysis 
and is therefore a defining gene for a metastatic signature [46].  
Gene expression changes in the cancer-associated stroma have proven important in predicting 
clinical outcome in breast cancer patients [12]. Other data indicates that the dynamic 
interaction between the epithelium and stroma plays an important role in governing the 
behaviour of a tumour. Overall, we observed relatively few gene expression changes in the 
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stromal samples along progression from normal through to IDC. This is consistent with 
recent reports where fewer gene expression changes were identified in the stromal 
compartments relative to the epithelial compartments during progression [11]. We 
exclusively used the interlobular stroma (surrounding the tumour, as opposed to intervening 
stroma) in order to avoid epithelial contamination within our stromal samples and this may 
explain the lack of correlation between our tumour-stroma gene lists and the two previously 
reported [5, 11]. It must also be noted that these two published stromal signatures do not 
significantly overlap with each other, despite being performed with FF samples. We found a 
set of five genes (USP19, MRAP2, EFCBP1, ABCB1 and FADH1) to be differentially 
expressed only when compared with normal stromal samples from reduction mammoplasties 
(RM-NS) using WG-DASL. Further, the most ‘normal’ stromal samples (BC-NS and RM-
NS) did not cluster together in the hierarchical clustering, suggesting that subtle gene 
expression changes exist between normal stroma from healthy and cancer patients.  
 
In summary, we have applied the WG-DASL assay for exploring gene expression pattern 
changes to address the clinically important scenario of progression from DCIS to IDC and the 
role played by both the epithelial and stromal compartments in this process. We found that 
the majority of expression changes during progression occurred within the epithelial cell 
compartments with relatively little change occurring in the stroma. Consistent with previous 
reports was the enrichment in biological processes related to extracellular matrix remodeling 
in IDC compared to DCIS, and specifically this related to the elevated expression of genes 
such as COL11A1, COL5A2 and MMP13 in epithelial cells of IDC. These genes might 
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therefore be playing a crucial role in facilitating the invasive of neoplastic cells into and 
through the surrounding stroma. 
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Figure Legends 
Fig.1: Epithelial and stromal components micro-dissected and analyses in this study 
.(A) Schematic detailing the two epithelial compartments (DCIS, IDC) and the three different 
cancer-associated stromal compartments selected (hatched). The respective distances from 
the epithelial lesions (DCIS or IDC) is given. (B-D) Haematoxylin and eosin stain of 
representative cases delineating regions microdissected: (B) focus of DCIS and associated 
stroma (within 3 mm; DCIS-S); (C) morphologically normal stroma dissected at a distance of 
>10 mm (BC-NS) from the lesion, in this instance, IDC; (D) focus of IDC and associated 
stroma (within 3 mm; IDC-S).  
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Fig.2: WG-DASL expression analysis of the epithelial and stromal compartments of DCIS 
and IDC patient samples 
(A) Hierarchical clustering of 69 successful samples using the 10,870 probes that 
demonstrated a 2-fold change (up or down) across the sample set. Individual genes are 
arranged in rows and samples in columns. IDC and DCIS epithelial samples (white) tended to 
cluster separately from the stromal samples (black). B: Supervised clustering analysis of the 
epithelial sample cohort using the 64 probes (58 genes) that were differentially expressed 
between DCIS and IDC (IDC grade 3, purple; IDC grade 2, pale blue; DCIS high-grade, 
yellow; DCIS intermediate (Int) grade, pink). (C) Unsupervised clustering of the stromal 
samples using all probes (>2 fold from the mean across the dataset); IDC-S, red; DCIS-S, 
blue; BC-NS, maroon; RM-NS, grey).  
Fig.3: Validation of gene expression changes in the epithelial and stromal components of 
DCIS and IDC lesions 
Selected transcripts were validated using qRT-PCR; the data is normalised to RPL13A1, is 
relative to a pooled normal reference and is presented as an RQ (relative quantitation) value. 
Statistical significance was calculated using the Mann-Whitney U test (GraphPad Prism 
version 5) and is indicated only where significant (*= P≤0.03, **= P≤0.01). (A) Expression 
changes in the epithelial compartment of IDC and DCIS samples are presented for MMP13, 
SFRP1, SOX10 and COL17A. (B) COL11A1 expression data for all sample types is presented. 
(C) Expression changes in ABCB1, MRAP and USP19 in the four stromal sample types (RM-
NS, IDC-S, DCIS-S and BC-NS).  
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Fig.4: Immunohistochemical analysis of SFRP1 and SOX10 expression in normal 
epithelium, DCIS and IDC 
(A)-(C) SFRP1 protein expression is observed in the normal luminal epithelial cells 
(arrowhead) as well as in stromal cells surrounding the TDLU; SFRP1 expression is reduced 
in DCIS (B) and in IDC (arrow in (C)) relative to normal epithelium (arrowhead in (C)). (D)-
(F) SOX10 is a specific marker of myoepithelial cells of normal terminal ductal lobular units 
(arrowhead in (D) and (F)), and of DCIS (arrowhead in (E)), whereas luminal epithelial cells 
of normal TDLUs ((D) and (F)) and neoplastic epithelium of DCIS (E) and IDC (arrow in 
(F)) lack SOX10 expression. 
Fig.5: Dual immunofluorescence for COL11A1 and CK8/18 in breast cancer progression 
Expression of COL11A1 was assessed in epithelial and stromal compartments of frozen 
sections from breast cancer patients containing normal TDLUs, DCIS and IDC and reduction 
mammoplasties containing normal TDULs. Co-staining was performed with the epithelial 
marker CK8/18 (red) and COL11A1 (green) to highlight the presence of co-expression (see 
merged image – right hand panel). Panel (A)-(C) breast cancer case with normal TDLU (A), 
DCIS (B) and IDC (C) showing reduced expression of COL11A1 in DCIS relative to IDC. 
Panels (D)-(E), breast cancer case with DCIS (D) and IDC (E) where COL11A1 was 
expressed to similar levels between the epithelial compartments. Panel (F), reduction 
mammoplasty case showing high COL11A1 expression in epithelium of normal TDLU. The 
left hand panel shows the DAPI counterstain (blue). 
 
 
